Table of Contents

Where this sits. This article is the "tolerance corrupts" node of the spikeopathy framework. It supplies a candidate mechanism for the clearance failure documented in Spike Persistence: Microclots, Reactivated Viruses, and Failed Clearance. The mechanism is real and peer-reviewed (Zhang et al., Nature 2025). The specific link to vaccine forensics is a hypothesis. Tag [HYPOTHESIS], confidence LOW-MODERATE until the bridging work in Part 5 lands.

Executive summary

Detection is not clearance. That is the entire thesis in four words, and the rest of this article unpacks why those four words may matter more than the vaccine debate has so far admitted.

A December 2025 paper from Edgar Engleman's group at Stanford (Zhang et al., Nature 2025, PMID 41372415) establishes a single signalling axis, EPO through EPOR on type 1 conventional dendritic cells (cDC1s), as the master switch between two immunological outcomes. When EPO-EPOR is active on cDC1s, the dendritic cells mature into a tolerogenic state and activate regulatory T cells (Tregs). When EPO-EPOR is blocked, the same dendritic cells mature into an immunogenic state and activate killer CD8+ T cells. The antigen is the same. The danger signals are the same. The outcome is decided by one hormonal switch.

Read alongside the cGAS-STING DNA-sensing literature, this places an uncomfortable question on the table. Residual plasmid DNA in mRNA vaccines (documented by Kämmerer and Steger 2024 at 32.71 to 43.38 ng per clinical dose, confirmed present by EMA under ASK-289849, with the full 11-feature plasmid map now independently annotated) is a classical trigger for cGAS-STING inflammatory sensing. cGAS-STING fires loudly. The Stanford finding implies the downstream decision, tolerance or clearance, is gated by EPO-EPOR. If EPO-EPOR is active in the wrong window, the contaminant is detected but the responding cell population is told to stand down.

This article does not claim that is what happens. It claims the mechanism is real, the components are documented, and the bridge between them is a testable hypothesis with explicit refutation criteria. The confidence level is LOW-MODERATE for the vaccine-specific link and HIGH for the underlying Stanford finding.

TL;DR

  • Stanford finding (HIGH confidence). EPO signalling through EPOR on cDC1s is the master switch between immune tolerance (Treg activation) and immune activation (killer T-cell activation). Zhang et al., Nature 2025, PMID 41372415.
  • Vaccine-forensic context (HIGH confidence on facts, MODERATE on the link). Residual plasmid DNA in BNT162b2 and mRNA-1273 is documented by Kämmerer/Steger, confirmed by EMA, and carries an intact SV40 enhancer/promoter in the Pfizer construct (695 bp, 8.9 percent of plasmid). cGAS-STING senses cytosolic DNA. This is the upstream detection arm.
  • Hypothesis (LOW-MODERATE confidence). The downstream fate of contaminant DNA, clearance or tolerance, is gated by EPO-EPOR status on cDC1s at the time of exposure. Post-vaccination tissue stress can elevate EPO. If the tolerance gate is open during that window, detection does not produce clearance.
  • What survives if the hypothesis fails. The Stanford finding stands on its own. The DNA-contamination forensics stand on their own. Only the specific bridge falls.
  • What would confirm the hypothesis. Bridging experiments in humanised mouse models measuring EPOR expression on cDC1s post-vaccination, plus Treg induction markers, plus persistence of contaminant DNA fragments. See Part 5.
  • What would refute the hypothesis. Demonstration that cGAS-STING activation by contaminant DNA proceeds to robust CD8+ T-cell clearance regardless of EPO-EPOR status. See Part 6.

Part 1: The Stanford finding

Evidence Level: [AN/PR] (animal and primary human ex vivo) Confidence: HIGH for the mechanistic claim; MODERATE for in-vivo clinical translation

Zhang and colleagues, working in Edgar Engleman's laboratory at Stanford, published in Nature in late 2025 that erythropoietin signalling through the erythropoietin receptor on type 1 conventional dendritic cells acts as a master regulator of the tolerogenic versus immunogenic maturation decision. The paper is:

Zhang J, et al. Erythropoietin receptor on type 1 conventional dendritic cells dictates immune tolerance. Nature. 2025. PMID 41372415. DOI: 10.1038/s41586-025-09824-z. PMC12929016.

The key findings, in plain language:

  1. EPOR is expressed on cDC1s. This was not previously appreciated. EPO was thought of as a red-cell hormone. The Stanford group showed that cDC1s, the dendritic-cell subset responsible for cross-presentation of antigens to CD8+ T cells, express EPOR on their surface.

  2. EPO through EPOR drives cDC1s into a tolerogenic maturation state. When EPO binds EPOR on a cDC1, the dendritic cell matures into a form that activates regulatory T cells (Tregs) rather than killer T cells. The antigen is presented, but the presentation is suppressive.

  3. Blocking EPO-EPOR on cDC1s flips the switch. When EPOR is deleted or blocked on cDC1s, the same dendritic cells mature into an immunogenic form that activates effector CD8+ T cells. In mouse tumour models, EPOR deficiency in cDC1s reduced tumour growth by enhancing anti-tumour T-cell immunity and increased the pool of precursor exhausted tumour-specific T cells.

  4. The mechanism is consistent with a broader tolerance literature. Total lymphoid irradiation (TLI) is known to induce systemic tolerance in transplant and autoimmune settings. TLI elevates EPO and upregulates EPOR on cDC1s. The Stanford finding identifies that axis as the mechanism: TLI works because it opens the EPO-EPOR tolerance gate on cDC1s.

  5. "Cold" tumours use the same axis. Hypoxic, EPO-producing tumours keep the tolerance gate open locally and evade immune clearance even when danger signals are abundant.

The therapeutic implication Engleman's group draws is bidirectional. For autoimmunity and transplant, push EPO-EPOR open to induce tolerance. For cancer, block it to permit clearance.

The implication for vaccine forensics is the one this article exists to draw.

Part 2: What this means for contaminant DNA forensics

Evidence Level: [PR/PP] for the forensics; [HYPOTHESIS] for the link

The vaccine-forensic side of the bridge is well-documented on this site.

  • Residual plasmid DNA is present in both BNT162b2 and mRNA-1273 vials. Kämmerer and Steger (2024) measured 32.71 to 43.38 ng per clinical dose after LNP disruption with 1 percent Triton-X-100 and RNase A treatment. EMA, under ASK-289849, has confirmed residual DNA is present and that the historical 10 ng/dose limit was exceeded in some batches by the Kämmerer methodology.
  • The plasmid carries an intact SV40 enhancer, early promoter, and origin of replication in the Pfizer construct (OR134577.1, 695 bp SV40 content, 8.9 percent of plasmid, 100 percent identity to SV40 strain 776). Moderna's plasmid (OR134578.1) has zero SV40 sequence. This is now independently annotated at 11-feature resolution.
  • SV40 enhancer is functional in mammalian cells, as EMA has confirmed under ASK-289849. It drives KanR/NeoR expression in the pCMV-Script-derived backbone (AF028239.1, Stratagene 1997), inherited via the pST vector family (Holtkamp et al. 2006, PMID 16926288).
  • cGAS-STING is the primary cytosolic DNA sensing pathway in mammalian cells. Cytosolic double-stranded DNA, including short plasmid fragments, activates cGAS, produces cGAMP, activates STING, and triggers type-I interferon and inflammatory cytokine release. This is textbook immunology.

The default reading of these facts in the critical literature is: contaminant DNA, cGAS-STING fires, inflammation follows, bad outcome. That reading is correct as far as it goes. It is incomplete in a way the Stanford finding now exposes.

cGAS-STING is a detection pathway. It produces a danger signal. The Stanford finding establishes that the response to danger signals from dendritic cells is not hard-wired to clearance. The response is gated by EPO-EPOR. If EPO-EPOR is active on cDC1s at the time the danger signal arrives, the dendritic cell matures tolerogenically, presents antigen to CD4+ T cells in a suppressive context, and induces Tregs rather than effectors. The danger was detected. The response was tolerance.

This is not a speculative chain. Each link is documented:

  • Contaminant DNA in vaccine vials: Kämmerer and Steger 2024, EMA ASK-289849 confirmations.
  • LNPs deliver DNA into the cytoplasm: confirmed in the Kämmerer fluorimetry paper (LNP-associated DNA entry into human cells under experimental conditions).
  • Cytosolic DNA activates cGAS-STING: textbook, established across more than a decade of primary literature.
  • EPO-EPOR on cDC1s gates the tolerogenic versus immunogenic decision: Zhang et al. Nature 2025.
  • Post-vaccination tissue stress and inflammation can elevate EPO locally and systemically: established in the EPO physiology literature, including the TLI transplant tolerance literature.

The bridge is the specific window. If the EPO-EPOR gate is open when the cGAS-STING signal arrives from contaminant DNA, the predicted outcome is detection-without-clearance. Spike protein from the vaccine mRNA would be produced, presented by the same cDC1s in a tolerogenic context, and the responding T-cell population would be tipped toward Treg induction rather than effector induction. Spike-loaded cells would be tolerated rather than cleared. Spike persistence would result.

The persistence article on this site documents that spike does persist, in subsets of vaccine recipients, for months to years. Patterson, Ogata, and Hulscher primary literature document the same. The tolerance-gate hypothesis supplies a candidate mechanism for why clearance fails in those subsets.

Part 3: The tolerance window hypothesis

Evidence Level: [HYPOTHESIS] Confidence: LOW-MODERATE

The specific claim, stated as plainly as possible:

In a subset of vaccine recipients, the post-vaccination tissue environment produces a transient EPO elevation that opens the EPO-EPOR tolerance gate on cDC1s during the window in which contaminant plasmid DNA is being sensed by cGAS-STING. The result is detection-without-clearance: the contaminant is registered as danger, the spike antigen is registered as self-tolerated, and the responding T-cell population is tipped toward tolerance rather than effector clearance. Spike-loaded cells survive. Spike persists.

Subsets matter here. The hypothesis does not require every vaccine recipient to enter the tolerance window. It requires that the window opens in some recipients under some conditions, and that those recipients are overrepresented in the cohort that goes on to develop persistent spike, post-vaccination syndromes, or both.

Plausible conditions that would open the window:

  1. High local EPO from injection-site reaction. A strong local inflammatory response to the LNP-mRNA complex produces local hypoxia, which produces local EPO. If contaminant DNA is being co-delivered in the same LNP particles, it arrives in a tissue environment where EPO is already elevated.
  2. Pre-existing elevated EPO from any cause. Chronic hypoxia, smoking, altitude, anaemia, endurance training. Any baseline condition that elevates EPO widens the permissive window.
  3. Genetic variation in EPOR expression on cDC1s. Inter-individual variation in dendritic-cell EPOR density would produce a distribution of gate-sensitivity across the population. High-EPOR-cDC1 individuals would be more readily tipped into tolerance.
  4. Repeat dosing. Each dose produces a fresh antigen load. If the first dose has already induced partial tolerance to spike, the second and third doses arrive in a tolerance-favoured context even before any EPO-specific effect.
  5. Batch-to-batch contaminant variability. Kämmerer/Steger and McKernan both report wide variation in residual DNA across batches. Batches at the high end of the DNA distribution would produce a stronger cGAS-STING signal and, under the tolerance-gate hypothesis, a stronger tolerance signal rather than a stronger clearance signal.

The prediction is that the post-vaccination syndrome cohort is enriched for combinations of these conditions. High local EPO, high EPOR expression, high contaminant DNA, repeat dosing, and a fresh tolerance induction from a prior dose.

This is testable. Part 5 specifies how.

Part 4: Why this is the right shape of explanation

Three observations that the tolerance-gate hypothesis explains cleanly and the alternative explanations handle awkwardly.

4.1 Persistence in a subset, not the cohort.

If contaminant DNA produced direct toxicity or robust clearance, the outcome should be either universal harm (toxicity) or universal clearance (no persistence). Neither is observed. What is observed is persistence in a subset. The tolerance-gate hypothesis predicts exactly that distribution: the gate opens in some recipients and not others, depending on EPO-EPOR status at the time of exposure.

4.2 Detection of spike and antibody class switching without clearance.

Vaccine recipients produce anti-spike antibodies. This is the success criterion for the vaccine and it works. What it does not produce, in the subset that develops persistence, is CD8+ T-cell clearance of spike-loaded cells. Antibody without cellular clearance is the signature of a tolerance-corrupted response, not the signature of a failed response. The tolerance-gate hypothesis predicts exactly this pattern: antibody persists (B-cell arm intact), CD8+ clearance fails (tolerance gate open on the cDC1 cross-presentation arm).

4.3 Tolerance to self-antigens on spike-transfected cells.

Case reports of autoimmune phenomena post-vaccination, including molecular mimicry against self-antigens and breakouts of latent autoimmunity, are documented in the pharmacovigilance record. The tolerance-gate hypothesis does not require tolerance only to spike. If cDC1s are tipped tolerogenic while presenting spike derived from transfected cells, they are also presenting whatever self-antigens those transfected cells express. Tolerance induction is not antigen-specific at the dendritic-cell maturation level. A tolerogenic cDC1 tolerises to everything it presents. The hypothesis predicts that autoimmune phenomena, where they occur, should cluster with spike persistence rather than distribute randomly.

None of these three observations is uniquely explained by the tolerance-gate hypothesis. Each has alternative accounts. The point is that the tolerance-gate hypothesis fits the three observations cleanly, with a single mechanism, while the alternatives require separate explanations for each.

Part 5: What would confirm this

The hypothesis is testable. The bridging work is concrete.

5.1 Humanised mouse model.

Dose humanised mice with a Pfizer-bivalent-equivalent LNP-mRNA preparation at the high end of the Kämmerer DNA range (approximately 40 ng DNA per dose). Sacrifice subsets at days 1, 3, 7, 14, 30. Measure:

  • EPOR expression on cDC1s in draining lymph node and spleen (flow cytometry).
  • EPO levels in serum and injection-site tissue (ELISA).
  • cGAS-STING activation markers (p-TBK1, p-IRF3, IFN-beta) in dendritic cells.
  • Treg induction in draining lymph node (FoxP3+ CD4+ T cells).
  • CD8+ T-cell activation against spike (tetramer staining).
  • Persistence of spike antigen and contaminant DNA in tissues (qPCR and immunohistochemistry).

Prediction: EPOR upregulation on cDC1s coincides with Treg induction and absent or muted CD8+ activation. Spike and DNA persist past day 30 in a subset.

5.2 EPOR blockade arm.

Repeat the mouse study with a cDC1-targeted EPOR blockade (or use EPOR-floxed x CD11c-Cre mice). Prediction: tolerance gate closes, CD8+ activation rises, spike clearance improves.

5.3 Human cohort study.

Recruit a post-vaccination syndrome cohort and matched controls. Measure baseline EPO, EPOR expression on circulating dendritic cells, Treg frequencies, anti-spike IgG, and spike persistence markers (S1 in monocytes, circulating spike). Prediction: syndrome cohort shows higher baseline EPO, higher EPOR on cDC1s, higher Treg frequencies, and detectable circulating spike, as a correlated signature.

5.4 Batch-stratified pharmacovigilance.

Use the batch-level residual DNA data (where regulators hold it) to stratify adverse-event reports. Prediction: batches at the high end of the DNA distribution show disproportionately elevated reporting rates for syndromes consistent with tolerance-corrupted clearance (autoimmune flares, persistent spike symptom clusters), not just elevated reporting rates of acute reactions.

None of these studies exists in the published literature at present. All four are within reach of a reasonably funded immunology laboratory. None requires any technology that has not already been validated.

Part 6: What would refute this

Scientific integrity requires naming the observations that would kill the hypothesis. The clearest refutations:

  1. cGAS-STING activation by contaminant DNA produces robust CD8+ T-cell clearance regardless of EPO-EPOR status. If a mouse study shows that contaminant DNA sensing proceeds directly to effector T-cell activation and antigen clearance with no tolerance signal, regardless of EPOR manipulation, the bridge is broken. The Stanford finding stands. The vaccine link does not.

  2. EPOR is not upregulated on cDC1s post-vaccination. If a human or mouse study fails to detect EPOR induction on cDC1s in the post-vaccination window, the gate never opens and the hypothesis fails. The Stanford finding is about baseline EPOR expression and induced upregulation. If vaccination does not induce it, there is no gate to open.

  3. Treg frequencies do not differ between persistent-spike and clearance cohorts. If a cohort study shows no correlation between Treg frequency and spike persistence, the tolerance-gate mechanism is not the operative one in the subset. Some other mechanism produces persistence.

  4. Batch-stratified pharmacovigilance shows no signal. If high-DNA batches do not cluster with tolerance-syndrome reports, the contaminant-DNA-specific arm of the hypothesis fails (although the broader spike-persistence mechanism is unaffected, since spike itself can induce tolerance through other pathways).

Each refutation is independently testable. The hypothesis can fall on any of them.

Part 7: What this article is not claiming

Calibrated claims survive better than uncalibrated ones. This article explicitly does not claim:

  • That the tolerance gate is the primary cause of post-vaccination syndromes. It is one candidate mechanism among several. The RAGE/IL-10 tolerance trap and the mTOR/p53 survival pathway covered in the persistence article are independent and may dominate.
  • That every vaccine recipient enters the tolerance window. The hypothesis is subset-specific by construction.
  • That spike persistence is solely a tolerance-gate phenomenon. Persistence has multiple documented mechanisms (cellular senescence, lysosomal dysfunction, mTOR survival). The tolerance gate is the upstream decision that permits those mechanisms to operate.
  • That contaminant DNA is the only input. Spike protein itself, presented in a tolerance-favoured context, can induce tolerance to spike. Contaminant DNA is the input that makes the prediction vaccine-batch-specific.
  • That EPOR blockade is a clinical recommendation. It is not. EPOR blockade has well-established risks (anaemia, hypertension, thrombosis). The therapeutic implication in humans is downstream of the bridging work, not this article.
  • That the vaccine programme should be halted on the basis of this hypothesis. That is a policy judgement that depends on benefit-risk calculus across the entire vaccinated population. This article supplies a candidate mechanism for a documented subset outcome. Policy is a separate question.

What this article does claim: the Stanford finding is real, published in Nature, and reshapes the framework within which the contaminant-DNA forensics have to be read. Detection is not clearance. The downstream decision is gated. The gate is nameable. The gate is testable.

Part 8: How this connects to the rest of the site

The tolerance-gate hypothesis is one of three candidate mechanisms for the failure of spike clearance documented across this site. It is not the only one, and it is not claimed to be the dominant one.

The case is not that one of these mechanisms is right and the others are wrong. The case is that they are mutually reinforcing, that each is testable independently, and that the cGAS-STING detection arm is well-documented while the tolerance-decision arm has just been clarified by the Stanford finding.

Part 9: Why the framing matters

The default framing in the critical literature is: contaminant DNA, cGAS-STING fires, inflammation, harm. That framing is correct as far as it goes, and it has been useful for getting the issue taken seriously. It is also incomplete in a way that a sophisticated defender of the regulatory position can exploit.

The incomplete framing predicts universal inflammation. The observed outcome is subset-specific persistence, mixed antibody-and-tolerance signatures, and clustered autoimmune phenomena. A sophisticated defender points to the gap between the predicted universal inflammation and the observed subset-specific outcome, and uses the gap to dismiss the mechanism.

The tolerance-gate framing predicts the subset-specific outcome from first principles. It predicts that antibody production proceeds while cellular clearance fails. It predicts that autoimmune phenomena cluster with persistence. It predicts that high-DNA batches produce tolerance-syndrome reports rather than acute-toxicity reports. Each prediction is independently testable.

That is the value of getting the mechanism right. Not rhetorical advantage. Predictive precision. The Stanford finding allows a sharper prediction than the simple cGAS-STING framing allowed, and sharper predictions are what move a debate forward.

Reproducibility and primary sources

Every claim in this article is traceable to a primary source.

The Stanford finding:

  • Zhang J, et al. Erythropoietin receptor on type 1 conventional dendritic cells dictates immune tolerance. Nature. 2025. PMID 41372415. DOI: 10.1038/s41586-025-09824-z. PMC12929016.

The contaminant DNA forensics:

  • McKernan K, et al. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of residual DNA. Genes Insights. 2024. GenBank deposits OR134577.1 (Pfizer bivalent, 7,810 bp) and OR134578.1 (Moderna bivalent, 6,777 bp).
  • Kammerer U, Steger K. BioNTech RNA-based COVID-19 injections contain large amounts of residual DNA including an SV40 promoter/enhancer sequence. Sci Public Health Policy Law. 2024;5:10. (32.71 to 43.38 ng/dose after LNP disruption and RNase A.)
  • Speicher DT, Rose HK, McKernan K. DNA fragments in mRNA vaccines: review of structure, function and implications. J Med Toxicol. 2025. PMID 40913499.
  • EMA/CHMP/BWP/482571/2023. BWP position on residual DNA in Comirnaty, adopted 31 October 2023, released under ASK-289849. Confirms SV40 elements present, functional, and undisclosed at MAA.

The 11-feature plasmid annotation:

  • OR134577.1 (BNT162b2 bivalent, 7,810 bp). 11-feature map resolved, 695 bp SV40 footprint (8.9 percent of plasmid, 100 percent identity to SV40 strain 776). Backbone confirmed as pCMV-Script-derived (AF028239.1) by three-way BLAST against pCMV-Script and pcDNA3.1(+), with four diagnostic KanR SNPs calling pCMV-Script in 4 of 4 positions. The SV40 block has been in BioNTech's pST mRNA platform since Holtkamp et al. 2006 (PMID 16926288), not introduced for BNT162b2. Full annotation and reproducible scripts in the linked toolkit analysis.

cGAS-STING and cytosolic DNA sensing:

  • Textbook immunology. Primary reviews include Ablasser and Chen, Nat Rev Immunol 2019, and Hopfner and Hornung, Nat Rev Mol Cell Biol 2020.

EPO-EPOR physiology and tolerance induction:

  • The TLI transplant tolerance literature is the relevant background. Engleman's group at Stanford has published the primary mechanistic work on cDC1 tolerance induction across the past decade.

The spike persistence record:

  • Patterson, Ogata, Hulscher primary literature. See the persistence article for full citation register.

The SV40 enhancer and lymphoid mutagenesis:

  • Senigl F, et al. SV40 enhancer drives somatic hypermutation in lymphoid tissue. Nature. 2024. PMID 39490533. (Relevant because tolerance-gate open means longer survival of spike-loaded cells in lymphoid tissue, widening the SV40-enhancer SHM window.)

Citation register (calibrated)

  • Zhang J, Engleman E, et al. Erythropoietin receptor on type 1 conventional dendritic cells dictates immune tolerance. Nature. 2025;640. PMID 41372415. DOI: 10.1038/s41586-025-09824-z. PMC12929016.
  • McKernan K, et al. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of residual DNA. Genes Insights. 2024;7:1-15. DOI: 10.33393/genesi.2024.0294.
  • Speicher DT, Rose HK, McKernan K. DNA fragments in mRNA vaccines: review of structure, function and implications. J Med Toxicol. 2025. PMID 40913499.
  • Kammerer U, Steger K. BioNTech RNA-based COVID-19 injections contain large amounts of residual DNA including an SV40 promoter/enhancer sequence. Sci Public Health Policy Law. 2024;5:10.
  • Senigl F, et al. SV40 enhancer drives somatic hypermutation. Nature. 2024. PMID 39490533.
  • EMA/CHMP/BWP/482571/2023. BWP position on residual DNA in Comirnaty, 31 October 2023.

End of tolerance-gate hypothesis article. This is a living document. If the bridging work in Part 5 lands, the hypothesis tag comes off. If the refutation criteria in Part 6 land, the article is retracted in line with the calibration discipline documented in the Calibrated Counter-Claims piece.